https://nova.newcastle.edu.au/vital/access/ /manager/Index en-au 5 https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:54994 Wed 27 Mar 2024 16:38:54 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:39998 Fri 15 Jul 2022 11:01:56 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:38954 90% passing 2%/2mm/10% threshold) and ≤ 1 mm positional accuracy at target-cord interface was required. Results: 19 centres were credentialed; 11 had on-site measurement. Delivery devices included linear accelerator, TomoTherapy and CyberKnife systems. Five centres did not achieve 90% gamma passing rate. Of these, three were out of tolerance (OOT) in low (<5Gy) dose regions and > 80% passing rate and deemed acceptable. Two were OOT over the full dose range: one elected not to remeasure; the other also had positional discrepancy greater than 1 mm and repeat measurement with a new plan was in tolerance. The original OOT was attributed to inappropriate MLC constraints. All centres delivered planned target-cord dose gradient within 1 mm. Conclusion: Credentialing measurements for vertebral SABR in a multi-centre trial showed although the majority of centres delivered accurate vertebral SABR, there is high value in independent audit measurements. One centre with inappropriate MLC settings was detected, which may have resulted in delivery of clinically unacceptable vertebral SABR plans.]]> Fri 11 Mar 2022 15:47:13 AEDT ]]>